Nama's AI scorecard currently rates Exelixis Strong Buy (8.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is EXEL's P/E ratio?

Exelixis trades at a trailing price-to-earnings ratio of 19.0.

When does EXEL report earnings?

Exelixis's next scheduled report is on Feb 9, 2027. Analysts expect EPS of $1.03.

What is the EXEL price target?

The median analyst price target from 14 analysts is $60.00, with a range of $41.00 – $78.00.

Is EXEL Shariah compliant?

Nama's AAOIFI-style screen reads Exelixis as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Exelixis (EXEL)

Healthcare · Biotechnology · NASDAQ

Exelixis (EXEL) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $16.98B, a trailing price-to-earnings ratio of 19.0 and a free-cash-flow yield of 4.3%. Over the most recent reported fiscal year, revenue grew 7.0% and free cash flow per share grew 40.0%. Nama's AI scorecard rates it Strong Buy, 8.8 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Strong Buy · 8.8/10

The top band of the Fundamental Verdict (8.6–10). As of Nov 7, 2026.

Momentum

Leading · +43.2% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-5.6%

How far the last close sits under the highest price of the past five years.

Market cap	$16.98B
Trailing P/E	19.0
Price / book	9.3
Price / sales	6.8
FCF yield	4.3%
Dividend yield	—
Gross margin	96.3%
Operating margin	40.2%
Net margin	35.5%
Revenue growth (YoY)	+7.0%
Revenue growth (3-yr annual)	+12.9%
EPS growth (YoY)	+52.2%
FCF/share growth (YoY)	+40.0%
Beta	0.5
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

EXEL earnings

Next report: Feb 9, 2027 (Q4 2026, EPS estimate $1.03). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	$0.94	$0.91	+3.3%	$658.70M
Q2 2026	Aug 5, 2026	$0.91	$0.86	+5.8%	$628.69M
Q1 2026	May 5, 2026	$0.87	$0.76	+14.5%	$610.81M
Q4 2025	Feb 10, 2026	$0.94	$0.81	+16.1%	$598.66M

EXEL analyst price target

Median target $60.00 from 14 analysts, ranging $41.00 – $78.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live EXEL data on Nama Insights →

EXEL FAQ

Is EXEL a buy?: Nama's AI scorecard currently rates Exelixis Strong Buy (8.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is EXEL's P/E ratio?: Exelixis trades at a trailing price-to-earnings ratio of 19.0.
When does EXEL report earnings?: Exelixis's next scheduled report is on Feb 9, 2027. Analysts expect EPS of $1.03.
What is the EXEL price target?: The median analyst price target from 14 analysts is $60.00, with a range of $41.00 – $78.00.
Is EXEL Shariah compliant?: Nama's AAOIFI-style screen reads Exelixis as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.